An interventional study of Allopurinal in Schizophrenia, sponsored by Bronx Psychiatric Center. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Bronx Psychiatric Center · Not applicable, Interventional, and Treatment
This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 10 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Bronx Psychiatric Center is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Allopurinal 300mg once daily by mouth for four weeks
Drug: Allopurinal
300mg once daily by mouth for four weeks
Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia
Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)
Time frame: baseline and 4 weeks
Simpson Angus Scale for Parkinsonism
Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)
Time frame: baseline and 4 weeks
Ten subjects were recruited, in-patients in a State Hospital, between 2005 and 2008
| Milestone | Allopurinal Treatment |
|---|---|
| Started | 10 |
| Completed | 8 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)
| scores on a scale | Allopurinal Treatment |
|---|---|
| Baseline | 95 ± 22 |
| End | 75 ± 17 |
Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)
| score on scale | Allopurinal Treatment |
|---|---|
| Baseline | 0.37 ± 0.74 |
| End | 1.75 ± 3.1 |
| mg/dL | Allopurinal Treatment |
|---|---|
| Baseline | 5.9 ± 1.7 |
| End | 3.8 ± 0.7 |
Collected over During the 4 week study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | — | 0/10 (0%) | 0/10 (0%) |
| Age, Categorical(Participants) | Group 1 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 0 |
| Age, Continuous(years) | Group 1 |
|---|---|
| Mean | 38 ± 9.3 |
| Sex: Female, Male(Participants) | Group 1 |
|---|---|
| Female | 2 |
| Male | 8 |
| Region of Enrollment(participants) | Group 1 |
|---|---|
| United States | 10 |
No study locations are listed for this record.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bronx Psychiatric Center